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1078–5Objective. To assess the efficacy of calcium dobesilate on the quality-of-life (QoL) of patients with chronic venous disease
(CVD).
Design. Randomised, parallel, double blind, placebo-controlled clinical trial.
Methods. Patients were recruited from vascular surgery clinics and randomised to 500 mg capsules of calcium dobesilate
twice a day for 3 months or placebo. The primary outcome measure was ‘QoL after 3 months’ treatment measured by the
specific Chronic Insufficiency Venous International Questionnaire (CIVIQ). Secondary outcomes were QoL at 12 months
and assessment of the CVD signs and symptoms. The principal analysis was undertaken on the intention-to-treat (ITT)
data.
Results. Five hundred and nine patients were recruited (246 to calcium dobesilate and 263 to placebo). The analysis of the
‘QoL after 3 months’ showed no significant differences between groups (p¼ 0.07). For secondary outcomes, oedema and
symptoms of CVD, there were no significant differences between groups. In a multi-factorial analysis, the ‘QoL at 12
months’ was better in the calcium dobesilate group than in placebo group (p¼ 0.02).
Conclusions. Treatment with calcium dobesilate was not found to be superior to placebo on the QoL of CVD patients. The
sustained effect of calcium dobesilate observed after treatment should be confirmed in future studies.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Controlled trial.Introduction
Pharmacological treatment is often prescribed for
Chronic Venous Disease (CVD) because surgery and
sclerotherapy are not always indicated and compliance
with compression treatments such as elastic stockings
is frequently poor. Flavonoids, horse chestnut extract,
pentoxifylline and other drugs have been found to
achieve considerable relief of the symptoms of
CVD.1,2,3 An international consensus symposium in
2005 concluded that venoactive drugs are effective inppendix lists the Chronic Venous Insufficiency Study Group,
ry Committee, Monitoring and External Audit.
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884/000358+ 08 $34.00/0  2007 European Society for Vasculathe management of venous symptoms based on pub-
lished clinical trials and the experience of experts. Cal-
cium dobesilate was given a level A recommendation.4
However, a more recent systematic review concludes
that clinical trials which provide this evidence have
limitations.5
Calcium dobesilate (2,5 dihydroxy-benzenesulfo-
nate) is a synthetic drug to treat CVD. It acts on the
endothelium of capillaries by blocking the hyper-
permeability, inhibiting platelet aggregation6 and
increasing red cell flexibility; these mechanisms con-
tribute to an oedema-protective effect.7 Three meta-
analyses5,8,9 have suggested that calcium dobesilate
has more efficacy than placebo relieving oedema
and some CVD symptoms. Heterogeneity has been
detected among the trials due to the differing criteria
in patient selection, stage of the disease, dosage of
calcium dobesilate used, and selection of primaryr Surgery. Published by Elsevier Ltd. All rights reserved.
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periods in all studies were relatively short.5 In none of
the calcium dobesilate clinical trials published to date,
has patient Quality-of-life (QoL) been measured with
a specific and validated scale for CVD.
Given the limitations of previous trials, uncertainties
about the efficacy of calcium dobesilate still remain.
Therefore, we designed a large trial with a long
follow-up, and more rigorous methodology which
includes a measure of QoL as a primary endpoint.Materials and Methods
Patients were recruited between June 2002 and April
2004, from vascular surgery clinics in 32 Spanish
hospitals. The Ethics Committee at each centre and
the Spanish Drugs Agency evaluated and approved
the study protocol. Written informed consent was
obtained from all patients.
The inclusion criteria were adults (18 years of
age) of either gender with CVD, CEAP clinical grades
1 to 610e12 and able to complete a QoL questionnaire.
Exclusion criteria included chronic or acute diseases
that limited compliance to the protocol, scheduled
surgery or sclerotherapy in the coming calendar
year, pregnant or lactating women, patients with aller-
gies or known intolerance to the study medication,
history of neutropoenia or leucopoenia, and a baseline
serum leucocyte count under 3,500/ml.
All patients were examined clinically, and a blood
analysis and duplex ultrasonography were performed
at baseline in order to confirm the presence of CVD
and to exclude other illness associated with leg oe-
dema. For clinical consistency throughout the study,
the limb with the more advanced disease at baseline
was assessed.
The allocation to treatmentwas randomised, central-
ised and computer stratified in blocks of 10 patients, by
Clinical CEAP classification and centre. One groupwas
assigned to 500 mg capsules of oral calcium dobesilate
twice a day for three months, and the other, to placebo
(inactive capsules of identical appearance and weight)
twice a day for the same period.
After the treatment period, patients were followed
up for nine months, making the total study length
one-year. Each patient was visited four times: visit 1
at baseline/pre-randomisation, visit 2 for treatment
assignment and treatment initiation (15 days after),
visit 3 at completion of treatment (3 months) and visit
4 for final visit, end of the study (12 months). All med-
ication was given to the patient at visit 2 and counted
for compliance at visit 3. Patientswere considered com-
pliant if the 80% or more of the medication was taken.QoL was measured using the Spanish validated
Chronic Insufficiency Venous International Question-
naire (CIVIQ)13 and was evaluated at visits 2, 3, and
4. Each visit also included a evaluation applying the
CEAP classification and measuring perimeter of the
ankle joint by the Leg-O-Meter14 and a 100 mm
Visual Analogue Scale (VAS) for the assessment of
oedema and symptoms, respectively. Duplex ultraso-
nography was performed to identify venous obstruc-
tion or reflux and to confirm the clinical diagnosis of
CVD but not to refute it. The superficial veins, deep
veins and perforating veins were assessed for venous
reflux. We considered that the normal valve closure
time for all veins in the standing position was 0.5 sec-
ond, and reflux was present if the duration of retro-
grade flow was longer than this.
Variables of study
The main outcome measure was the QoL after three
months of treatment measured by the CIVIQ ques-
tionnaire. Secondary outcome measures were QoL at
the end of follow-up period (12 months); CVD signs
(oedema) and symptoms (pain, heaviness, cramps,
swelling, venous claudication, itching); and tolerance
and safety of the treatment.
Sample size
The estimated sample size was 253 patients per arm,
calculated from the GRANMO 5.0 statistical pro-
gram.15 An improvement of 10 points was hypothe-
sized for the active group as compared to the
placebo group in the overall CIVIQ score, which
ranges from 0 to 100 points. The approximation of
the analysis was bilateral. The values for the calcula-
tion of probability errors type I and type II were set
at 0.05 and 0.10 respectively. The percentage of pa-
tients that would withdraw from the study or who
would be lost to follow-up was estimated at 25%.
Statistical analysis
The analysis of efficacy was made on an intention-to-
treat (ITT) basis. Additionally, a ‘per protocol’ analysis
was performed.
Patients’ baseline characteristics were compared
before treatment was started to assess similarity of
the two groups.
The main outcome was the comparison between
groups in the overall CIVIQ score after three months
of treatment. The CIVIQ included twenty questions,
each with a score of 0 to 5. It assessed four QoLEur J Vasc Endovasc Surg Vol 35, March 2008
509 randomized patients
Calcium dobesilate
246 patients
Visit 1
Pre-treatment
Visit 2
mo 0
Start treatment
Placebo
263 patients
208 patients
(84.6 )
222 patients
(84.4 )
360 M. J. Martı´nez-Zapata et al.domains: physical, psychological and social limita-
tions, and pain. Analysis was based on the overall
scores for each domain of the QoL questionnaire.
The scores for each domain were standardised accord-
ing to the method adopted by J. Ware for SF36.16 The
overall score or total QoL was obtained by the arith-
metic sum of all domains to obtain a result between
0% (best QoL) and 100% (worst QoL). In the ITT anal-
ysis, the last available data (if there was any) or the
worst (if there was no final data point) CIVIQ score
were assigned to the missing data point.
For the evolution of the CIVIQ score, two-way anal-
ysis of variance (ANOVA) was performed. The factors
were group (calcium dobesilate, placebo), time (base-
line, the end of 3 months of treatment) and interaction
between them. QoL was also evaluated throughout
the study, from baseline to the end of follow-up.
A multi-factor ANOVA was used to assess other
factors that could influence symptoms or oedema in
CVD. The factors were age, gender, use of elastic
stockings, physical therapy, previous venous surgery,
sclerotherapy, venous thrombosis or pulmonary
thromboembolism, certain concomitant medications
(diuretic, analgesics, non-anti-inflammatory steroids
drugs, corticosteroids), and associated diseases (renal,
hepatic, or cardiac insufficiency). The ANOVA were
undertaken by the Generalised Linear Models
(GLM) procedure.
The main outcome measure was the change in QoL
following treatment and during following up in the
entire group. At a later stage we considered that a se-
ries of 5 subgroup analyses of QoL might be informa-
tive. We considered the seasonal recruitment period,
only patients with symptomatic CVD, only patients
with CEAP 3, CEAP 4, 5 and 6 venous disease, and
analysing by CIVIQ dimensions.
For some secondary outcomes (such as oedema,
pain or cramps), a student t test or a chi-square test
were used depending on the quantitative or categori-
cal values. For quantitative values the mean and stan-
dard deviation (SD) were calculated. An intermediate
analysis was performed with the first 250 patients to
assess the safety profile of calcium dobesilate. The sta-
tistical package SPSSwin 11.5, SPSS Inc, Chicago, Ill.
was used for all analysis.Visit 3
mo 3
End of treatment
Visit 4
mo 12
End of follow-up
197 patients
(80.0 )
216 patients
(82.1 )
185 patients
(75.2 )
193 patients
(73.4 )
Fig. 1. Flow of patients in the clinical trial.Results
The study included 509 patients with CVD, 443 (87%)
of whom were women and 66 (13%) men; 246 (48.3%)
patients were assigned to calcium dobesilate and 263
(51.7%) to placebo. A total of 378 patients (74.3%)
completed the follow-up with no differences betweenEur J Vasc Endovasc Surg Vol 35, March 2008the two groups: 185 (75.2%) patients in the calcium
dobesilate group and 193 (73.4%) in the placebo group
(P¼ 0.68). One hundred and thirty-one (25.7%) pa-
tients withdrew from the clinical trial (Fig. 1). The
principal causes of withdrawal were voluntary deci-
sion not to continue (45.8%), follow-up loss (13.7%),
protocol deviation (11.5%) and concurrent pathologies
(9.2%). At baseline, 95% of patients in the dobesilate
group and 96% in the placebo group had some degree
of disability related to CVD (Table 1). The distribution
of the CEAP classification was similar in both groups
and the most frequent were 29.1% of patients with
CEAP 2 (varicose veins), 26.3% with CEAP 3 (oedema
without skin changes), and 23.8% with CEAP 4
(chronic skin disorders) (Table 2). All patients with
CEAP 1, 5 and 6 were symptomatic. The patients
with CEAP 2, 3 and 4 were symptomatic in the
96.3%, 97.6% and 98.1% of cases, respectively. The
clinical history was similar between groups, except
for diabetes mellitus, prolonged standing, physical
therapy and venous claudication that were more fre-
quently seen in the placebo group. Chronic hepatitis
was more frequent in the calcium dobesilate group
(Table 3). Those clinical factors were included in the
multifactorial analysis.
Patient QoL at baseline differed during winter and
summer (47.0 and 48.2, respectively) compared to the
spring and autumn (42.0 and 42.7, respectively)
( p¼ 0.045). But the seasonal period of recruitment
did not result in any difference in patient QoL when
groups were compared at baseline ( p¼ 0.829).
The ITT results for the main outcome, overall
CIVIQ score after three months’ treatment, showed
Table 1. Baseline Characteristics of Patients
Calcium
dobesilate
Placebo P
N¼ 246 N¼ 263
Age (mean and SD) 53.3 (13.3) 54.7 (14.9) 0.27
Male/Female 29/217 37/226 0.51
CEAP Disability Score N¼ 243 N¼ 259
Asymptomatic 12 (4.9) 10 (3.9) 0.73
Symptomatic but functional
without elastic support
164 (67.5) 185 (71.4)
Symptomatic but functional
with 8 h of elastic support
60 (24.7) 59 (22.8)
Incapable of working 7 (2.9) 5 (1.9)
Location of the reflux/obstruction
by duplex ultrasound
N¼ 242 N¼ 253
Obstruction femoral 17 (7.0) 13 (5.1) 0.45
popliteal 14 (5.8) 14 (5.8) 1.00
Reflux popliteal vein above
the saphenopopliteal
junction
11 (4.5) 11 (4.3) 1.00
popliteal vein under
the saphenopopliteal
junction
15 (6.2) 14 (5.5) 0.84
internal saphenous 135 (55.8) 132 (52.2) 0.47
external saphenous 26 (10.7) 33 (13.0) 0.48
femoral vein above
the saphenofemoral
junction
18 (7.4) 18 (7.1) 1.00
femoral vein under
the saphenofemoral
junction
19 (7.9) 18 (7.1) 0.86
perforating veins 58 (24.0) 64 (25.3) 0.75
Table 2. CEAP at baseline
Calcium
dobesilate
Placebo P
N¼ 246 N¼ 263
Value of clinical CEAP n (%) n (%)
1 (Telangiectases,
reticular veins)
35 (14.2) 37 (14.1) 0.47
2 (Varicose Veins) 61 (24.8) 87 (33.1)
3 (Oedema with no
skin changes)
70 (28.5) 64 (24.3)
4a (Pigmentation, eczema) 28 (11.4) 35 (13.3)
4b (Lipodermatosclerosis,
white atrophy)
34 (13.8) 24 (9.1)
5 (Healed Ulcer) 12 (4.9) 11 (4.2)
6 (Active Ulcer) 6 (2.4) 5 (1.9)
Anatomical alteration N¼ 242 N¼ 252
Superficial veins 203 (83.9) 217 (86.1) 0.52
Deep veins 36 (14.9) 30 (11.9) 0.35
Perforator veins 48 (19.8) 45 (17.5) 0.64
CVD Aetiology
Primary 208 (86.0) 230 (91.3) 0.06
Secondary 26 (10.7) 20 (7.9) 0.35
Congenital 11 (4.5) 9 (3.6) 0.65
n/N (%) n/N (%)
Venous Reflux by
Eco-Doppler
151/246 (61.4) 165/263 (62.7) 0.78
Venous Obstruction
by Eco-Doppler
16/253 (5.3) 17/242 (7,0) 0.85
Table 3. Clinical antecedents
Calcium
dobesilate
n/N (%)
Placebo
n/N (%)
P
Cardiac Insufficiency 7/234 (3.0) 12/256 (4.7) 0.35
Chronic Hepatitis 4/244 (1.6) 0/258 (0) 0.05
Chronic Renal
Insufficiency
1/245 (0.4) 4/260 (1.5) 0.37
Compression bandage 8/231 (3.5) 7/242 (2.9) 0.79
Deep venous thrombosis 20/240 (8.3) 15/260 (5.8) 0.29
Diabetes Mellitus 6/244 (2.4) 23/260 (8.8) 0.00
Elastic compression 77/241 (31.9) 77/254 (30.3) 0.69
Physical therapy 12/244 (4.9) 25/256 (9.8) 0.04
Previous gestation 189/242 (78.0) 182/254 (71.6) 0.12
Prolonged Standing 187/245 (76.3) 217/260 (83.5) 0.058
Pulmonary
Thromboembolism
3/243 (1.2) 5/256 (1.9) 0.72
Sclerotherapy 41/244 (16.8) 43/260 (16.5) 1.00
Superficial venous
thrombosis
43/240 (17.9) 37/257 (14.3) 0.32
Venous Claudication 3/242 (1.2) 11/260 (4.2) 0.05
Venous surgery 61/245 (24.9) 57/261 (21.8) 0.46
Venous Ulcer 7/244 (2.9) 6/257 (2.3) 0.78
Venous Ulcer Recidivate 4/124 (3.2) 1/129 (0.8) 0.20
361Calcium Dobesilate for Chronic Venous Diseasea significant overall improvement in both groups with
no significant differences between groups (P¼ 0.07).
The mean baseline CIVIQ score was 44.5 (22.4) in
the dobesilate group and 47.5 (22.3) in the placebo
group. At the end of the three-month period, the
mean CIVIQ scores were 37.8 (22.6) and 38.2 (23.8), re-
spectively. Overall, a significant reduction of 8 points
(8%) was observed compared to the baseline value
(P¼ 0.001) (Fig. 2).10
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Fig. 2. Quality-of-life at three months of treatment. Evolu-
tion Visit2-Visit3: P¼ 0.00. Comparison between treatments
Visit2-Visit3: P¼ 0.07.
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analysis were similar to the principal analysis, and
both groups were better in the overall score CIVIQ af-
ter three months’ treatment, without any significant
difference between them. The ‘per protocol’ analyses
showed similar results.
The multi-factorial analysis of the overall CIVIQ
score of the after three months’ treatment showed no
significant differences between groups (P¼ 0.54).
Analysis of the QoL (measured by CIVIQ) at 12months
showed a significant difference in favour of the
calcium dobesilate treated group (P¼ 0.02) (Fig. 3).
For oedema and CVD symptoms, both groups
experienced a reduction in the mean malleolar perim-
eter after treatment of 3.3 mm (P¼ 0.99). Furthermore,
the symptoms ameliorated in both groups, with
a mean reduction VAS range of 9.0 mm to 13.2 mm.
There were no significant differences between groups
(Table 4).
Of the patients, who did not complete the study
due to serious adverse events, three in the calcium do-
besilate treated group were lost due to digestive intol-
erance (gastric pain, nausea and vomiting) and three
in the placebo treated group were lost due to digestive
intolerance, urticaria and Burkitt’s Lymphoma. There
were no cases of agranulocytosis or death during the
study. No significant differences were found between
groups in the number of patients with an adverse
event (Table 5).10
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Fig. 3. Progression of quality-of-life score throughout the
study. Multi-factor ANOVA. Evolution Visit2-Visit3-Visit4:
P¼ 0.37. Comparison between treatments Visit2-Visit3-
Visit4: P¼ 0.02.
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To date, clinical studies evaluating the efficacy of
calcium dobesilate on CVD have focused on signs,
symptoms or physiological parameters. In the present
study we evaluated the efficacy of this drug in CVD by
measuring the patients’ QoL. This important clinical
outcome was assessed using the CIVIQ questionnaire,
a specific instrument that has been internationally
validated.13
The number of patients recruited makes this study
the largest randomized, placebo-controlled, double-
blind calcium dobesilate clinical trial to date and the
second largest with a drug for CVD. Furthermore,
the follow-up was longer- nine months - than others
similar clinical trials.
The general characteristics of the study sample are
consistent with studies developed in Spain17 and in
others European countries.18 Most of the recruited
patients were middle-aged women with moderate
CVD. It is important to mention that most of the pa-
tients were symptomatic and a high percentage had
a history of prolonged standing. The CVD symptoms
were reflected in the QoL score at baseline assess-
ment and many participants presented some degree
of functional limitation. Although patients were
more symptomatic according to QoL measurements
during winter and summer, the seasonal period of
recruitment did not result differences between
groups.
The patients in the calcium dobesilate group expe-
rienced a modest improvement after three months
treatment, as suggested by a 7-point decrease (7%)
from the baseline QoL score, but that was not statisti-
cally different from the improvement observed in the
placebo group (9-point; 9%).
Initially, we anticipated a 25% withdrawal rate
when designing the study, bearing in mind the long
duration of the trial. The observed withdrawal rate
was 26% and surprisingly the majority of withdrawals
occurred during the recruitment period. The run in of
the clinical trial coincided with the decision of the
Spanish Drug Agency to remove CVD as an indication
for calcium dobesilate treatment (http://www.
hsanmillan.es/farma/flebotonicos.htm) because an
unfavourable risk-benefits balance. This may have
adversely affected recruitment to the study resulting
in a long recruitment period.
Although patients were randomised and there was
a similar percentage of withdrawals between groups,
some baseline differences were detected. However,
those factors did not have any influence in the main
outcome results since the adjusted analyses did not
modify the principal results.
Table 4. Comparison of signs and symptom score between groups e all data mean (standard deviation)
Assigned Treatment
(n patients)
Baseline
Score Mean (SD)
Post-treatment
Score Mean (SD)
P
Edema (mm) Placebo (203) 270.1 (54.8) 266.8 (53.9) 0.99
Calcium dobesilate (193) 258.2 (43.1) 254.9 (43.2)
Symptoms (VAS; mm)
Pain Placebo (216) 50.3 (26.1) 37.8 (27.4) 0.55
Calcium dobesilate (203) 48.8 (26.9) 37.8 (25.8)
Swelling Placebo (214) 50.7 (50.1) 37.5 (27.8) 0.38
Calcium dobesilate (203) 45.8 (29.0) 36.2 (28.6)
Heaviness Placebo (214) 59.7 (25.5) 46.9 (28.8) 0.75
Calcium dobesilate (203) 55.2 (27.3) 44.5 (28.4)
Cramps Placebo (211) 35.9 (31.5) 26.9 (28.7) 0.69
Calcium Dobesilate (204) 34.3 (31.5) 24.1 (27.1)
Venous Claudication Placebo (213) 34.6 (30.4) 23.6 (26.2) 0.19
Calcium dobesilate (205) 30.5 (29.7) 23.1 (27.4)
Itching Placebo (212) 42.2 (33.4) 31.3 (30.4) 0.40
Calcium dobesilate (204) 42.4 (33.5) 35.9 (68.6)
363Calcium Dobesilate for Chronic Venous DiseaseOne of the main findings in this study is the benefi-
cial effect observed in the placebo group at the end of
three months’ treatment in relation to the QoL. The
therapeutic effect of placebo is well known, especially
in treatment of pain.19 Optimization of patient care
during the study probably also contributed to the im-
provement in the placebo group. At least, this result
shows the importance of including a placebo group
in clinical trials to evaluate the drugs effects in CVD.
Several clinical studies have reported the efficacy of
calcium dobesilate in oedema and in some symptoms
related to chronic venous insufficiency.20e25 Although
our present results do not confirm these findings, it
should be kept in mind that assessment of signs and
symptoms of CVD was a secondary endpoint in our
study. A recent clinical trial24 evaluated oedema at-
tributable to CVI and showed that calcium dobesilate
was better than placebo. A 24% reduction in oedema
volume was found in CVI patients. This study evalu-
ated oedema by volumetric methods while our study
measured the ankle circumference, a less precise mea-
sure. The drug dose was lower in our trial than in
Labs24 study so that a dose-dependent effect may ex-
plain the difference in findings. The reason for choos-
ing a 1000 mg/day dose of calcium dobesilate in ourTable 5. Patients with adverse effects
Calcium dobesilate
N¼ 246
Placebo
N¼ 263
n (%) n (%)
Total adverse events 46 (18.7) 45 (17.1)
Adverse events related
to the medication
24 (9.7) 20 (7.6)
Withdrawal of treatment 12 (4.9) 11 (4.2)
Severe adverse effects 6 (2.4) 7 (2.7)
Severe adverse effects
related to the medication
1 (0.4) 1 (0.4)trial was that previous studies had shown efficacy
and that this dose was licensed for clinical use when
the study was commenced.21,22
The adjusted analysis by factors that were consid-
ered able to influence the final results of the QoL at
the end of three months’ treatment demonstrated no
differences between the two groups. However, at the
nine-month follow-up we observed statistically signif-
icant differences in the progression of the QoL be-
tween the two groups that favoured the calcium
dobesilate group. Thus after completing the treat-
ment, the beneficial effect of calcium dobesilate re-
mained or slightly increased over the nine-month
follow-up, but the placebo group worsened by the
end of the study with respect to baseline. These obser-
vations suggest the possibility of sustained therapeu-
tic action of the calcium dobesilate in the CVD
compared to placebo. Since this observation is based
on a secondary analysis, a new clinical study would
be needed to investigate this effect.
There was no significant difference in adverse
events between the treatment groups. During the clin-
ical study, no relevant adverse effects related to the
calcium dobesilate were detected. Nevertheless, the
study sample was not large enough nor the follow-
up period long enough adequately to assess the safety
of the medication with respect to agranulocytosis, an
infrequent and severe adverse effect, observed in
a case-population study.26
In conclusion, calcium dobesilate was as effective as
placebo in improving the QoL of CVD patients at the
end of three months’ treatment. No significant differ-
ences in secondary outcomes were observed between
the two groups. The sustained effect of improved
QoL in the calcium dobesilate group after withdrawal
of the drug should be studied in future trials and
evaluated in patients with more advanced CVD.Eur J Vasc Endovasc Surg Vol 35, March 2008
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